BRIEF published on 11/21/2025 at 11:25, 11 months 10 days ago Crossing of thresholds by Samsara BioCapital at INVENTIVA Voting Rights Capital Increase Threshold Crossing Inventiva Samsara BioCapital
PRESS RELEASE published on 11/13/2025 at 15:21, 11 months 18 days ago Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
BRIEF published on 11/13/2025 at 08:45, 11 months 18 days ago Inventiva Announces Temporary Trading Halt on Euronext Paris Euronext Paris Nasdaq Trading Halt Inventiva ADS Offering
PRESS RELEASE published on 11/13/2025 at 08:40, 11 months 18 days ago Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris Inventiva temporarily halts trading of ordinary shares on Euronext Paris for public offering preparation, with expected resumption by end of day. Company focuses on MASH treatment research Euronext Paris Trading Halt Public Offering Inventiva MASH Treatment
BRIEF published on 10/14/2025 at 22:05, 1 year ago Inventiva Launches New ATM Program to Raise $100 Million Biopharmaceutical SEC Filing Inventiva Lanifibranor ATM Program
PRESS RELEASE published on 10/14/2025 at 22:00, 1 year ago Inventiva Announces the Implementation of a New ATM Program Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF published on 10/07/2025 at 22:05, 1 year ago Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE published on 10/07/2025 at 22:00, 1 year ago Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF published on 10/01/2025 at 08:35, 1 year 1 month ago Andrew Obenshain Appointed as CEO of Inventiva Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
PRESS RELEASE published on 10/01/2025 at 08:30, 1 year 1 month ago Inventiva Appoints Andrew Obenshain as Chief Executive Officer Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
Published on 10/30/2026 at 23:35, 2 days 8 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 8 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 13 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 16 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 08:18, 6 minutes ago Score Capital AG reports strong growth in the first nine months of 2026: EBIT rises 63%, new business reaches EUR 171m
Published on 11/02/2026 at 08:10, 14 minutes ago STEICO SE: Change in the finance department – Ivica Rajković will succeed Georg Faller as CFO on 9 November 2026
Published on 11/02/2026 at 08:05, 19 minutes ago HIZENERGY Retains BloombergNEF Tier 1 Status Amid Tighter Q4 2026 Evaluation Criteria
Published on 11/02/2026 at 08:05, 19 minutes ago YeePay Explores New Approaches to Airline B2B Order Payments at IATA WFS & WPS 2026
Published on 10/30/2026 at 23:00, 2 days 9 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 14 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 20 hours ago Capital increase through exercise of subscription rights
